Trial Profile
Phase II Trial of Ponatinib in Patients With Bevacizumab-Refractory Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 05 Jun 2018 Status changed from active, no longer recruiting to discontinued, according to the results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 09 Aug 2017 Planned End Date changed from 1 Apr 2023 to 1 Jul 2018.